2. Search Result
Search Result
Results for "

proliferative disease

" in MedChemExpress (MCE) Product Catalog:

107

Inhibitors & Agonists

1

Fluorescent Dyes

4

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

15

Natural
Products

5

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0988
    Deferoxamine mesylate
    Maximum Cited Publications
    397 Publications Verification

    Desferrioxamine B mesylate; DFOM

    		 Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate
  • HY-B1625
    Deferoxamine
    Maximum Cited Publications
    397 Publications Verification

    Deferoxamine B; Deferriferrioxamine B; Deferrioxamine

    		 HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine
  • HY-B0617
    S-Adenosyl-L-methionine
    20+ Cited Publications

    S-Adenosyl methionine; Ademetionine; AdoMet

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine
  • HY-P1240
    MOG (35-55) mouse, rat
    5+ Cited Publications

    Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat

    		 Endogenous Metabolite Neurological Disease Inflammation/Immunology
    MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling .
    MOG (35-55) mouse, rat
  • HY-B0633A
    Hyaluronic acid
    15+ Cited Publications

    Hyaluronan; Hyaluronate

    		 Endogenous Metabolite Bacterial Akt PI3K Infection Neurological Disease Inflammation/Immunology Cancer
    Hyaluronic acid is a biopolymer composed of repeating units of disaccharides with various applications. Hyaluronic acid is a major component of the extracellular matrix (ECM). Hyaluronic acid is synthesized at the plasma membrane. Increased hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion and angiogenesis in digestive cancers. Hyaluronic acid participates in tissue remodeling and rapid cell proliferation in some physiological processes including embryonic morphogenesis and wound-healing. Hyaluronic acid activates the PI3K-Akt signaling. Hyaluronic acid acts as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting proteolytic MMP-9 binding to cell surface or stimulating MMP-9 binding to cell surface. Hyaluronic acid can be used as drug delivery for sodium butyrate to improve the anti-proliferative activity on breast cancer cell line. Hyaluronic acid can be studied in joint diseases, wound healing and cancer .
    Hyaluronic acid
  • HY-B0633
    Hyaluronic acid sodium
    15+ Cited Publications

    Sodium hyaluronate

    		 Endogenous Metabolite Bacterial PI3K Akt Inflammation/Immunology Cancer
    Hyaluronic acid sodium (Sodium hyaluronate) is a biopolymer composed of repeating units of disaccharides with various applications. Hyaluronic acid sodium is a major component of the extracellular matrix (ECM). Hyaluronic acid sodium is synthesized at the plasma membrane. Increased hyaluronic acid sodium levels are associated with tumor cell growth, adhesion, migration, invasion and angiogenesis in digestive cancers. Hyaluronic acid sodium participates in tissue remodeling and rapid cell proliferation in some physiological processes including embryonic morphogenesis and wound-healing. Hyaluronic acid sodium activates the PI3K-Akt signaling. Hyaluronic acid sodium acts as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid sodium also enhances cell invasion and angiogenesis by promoting proteolytic MMP-9 binding to cell surface or stimulating MMP-9 binding to cell surface. Hyaluronic acid sodium can be used as drug delivery for sodium butyrate to improve the anti-proliferative activity on breast cancer cell line. Hyaluronic acid sodium can be studied in joint diseases, wound healing and cancer .
    Hyaluronic acid sodium
  • HY-W017770
    S-Adenosyl-L-methionine disulfate tosylate
    20+ Cited Publications

    Ademetionine disulfate tosylate; S-Adenosyl methionine disulfate tosylate; AdoMet disulfate tosylate

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (Ademetionine) disulfate tosylate is the disulfate tosylate form of S-Adenosyl-L-methionine (HY-B0617). S-Adenosyl-L-methionine disulfate tosylate is an orally active methyl group donor. S-Adenosyl-L-methionine disulfate tosylate is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine disulfate tosylate also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine disulfate tosylate has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine disulfate tosylate
  • HY-156677
    STC-15
    4 Publications Verification

    		 METTL3 Cancer
    STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .
    STC-15
  • HY-B0617A
    S-Adenosyl-L-methionine tosylate
    15+ Cited Publications

    S-Adenosyl methionine tosylate; Ademetionine tosylate; AdoMet tosylate

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) tosylate is an orally active methyl group donor. S-Adenosyl-L-methionine tosylate is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine tosylate also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine tosylate has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine tosylate
  • HY-14614A
    S-Adenosyl-L-methionine chloride dihydrochloride
    5+ Cited Publications

    S-Adenosyl methionine chloride dihydrochloride; Ademetionine chloride dihydrochloride; AdoMet chloride dihydrochloride

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) chloride dihydrochloride is an orally active methyl group donor. S-Adenosyl-L-methionine chloride dihydrochloride is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine chloride dihydrochloride also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine chloride dihydrochloride has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine chloride dihydrochloride
  • HY-B0617S
    S-Adenosyl-L-methionine-d3

    S-Adenosyl methionine-d3; Ademetionine-d3; AdoMet-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine-d3 (S-Adenosyl methionine-d3) is the deuterated product of S-Adenosyl-L-methionine (HY-B0617). S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine-d3
  • HY-76711
    Naltrexone

    		Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight .
    Naltrexone
  • HY-B0644
    Sucralfate

    Sucrose octasulfate-aluminum complex

    		 Bacterial Infection Inflammation/Immunology Cancer
    Sucralfate (Sucrose octasulfate-aluminum complex) is a potent and orally active gastroprotectant with no systemic effects. Sucralfate inhibits peptic activity and binds to negatively charged subepithelial proteins exposed during mucosal injury, forming a viscous layer that protects the vascular bed and proliferative zone. Sucralfate is used for prevention and research of several gastrointestinal diseases in vivo .
    Sucralfate
  • HY-P1240A
    MOG (35-55) TFA
    5+ Cited Publications

    Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA

    		 Endogenous Metabolite Neurological Disease Inflammation/Immunology
    MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling .
    MOG (35-55) TFA
  • HY-B1153
    Glafenine
    4 Publications Verification

    Glafenin

    		 COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Metabolic Disease Inflammation/Immunology
    Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine
  • HY-112296
    T025
    4 Publications Verification

    		 CDK Apoptosis DYRK Cancer
    T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .
    T025
  • HY-B0328
    Triamcinolone
    2 Publications Verification

    		 Glucocorticoid Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Triamcinolone is a long-acting corticosteroid with anti-inflammatory, anti-oedematous, anti-proliferative, anti-angiogenetic, immunomodulatory and neuroprotective effects through binding to glucocorticoid receptors. Triamcinolone can relieve several dermatitis, immune diseases and ocular diseases .
    Triamcinolone
  • HY-10447
    Terameprocol

    EM-1421

    		 Survivin COX TNF Receptor Apoptosis Infection Inflammation/Immunology Cancer
    Terameprocol is an inhibitor targeting the Sp1 transcription factor, which can selectively inhibit the transcription of Sp1-dependent genes. Terameprocol exerts its effects by inhibiting Sp1-mediated gene transcription, such as reducing the expression of genes like CDC2, survivin and HMGB1, thereby arresting the cell cycle, inducing apoptosis, and suppressing the inflammatory response. Terameprocol exhibits anti-proliferative, pro-apoptotic, and anti-inflammatory activities and is currently mainly used in the research of diseases such as cancer and pulmonary arterial hypertension[1][2][3].
    Terameprocol
  • HY-114491
    Rineterkib

    		ERK Raf Cancer
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib
  • HY-B0617S2
    S-Adenosyl-L-methionine-13C dihydrochloride

    S-Adenosyl methionine-13C dihydrochloride; Ademetionine-13C dihydrochloride; AdoMet-13C dihydrochloride

    		 Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine- 13C (S-Adenosyl methionine- 13C) dihydrochloride is the 13C labeled S-Adenosyl-L-methionine (HY-B0617). S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine-13C dihydrochloride
  • HY-N3980
    Guaiol
    1 Publications Verification

    Champacol; Guaiac alcohol

    		 Autophagy RAD51 Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC50 of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions [4]
    Guaiol
  • HY-147135
    MYF-03-69
    1 Publications Verification

    TEAD-IN-3

    		 YAP Apoptosis Cancer
    MYF-03-69 (TEAD-IN-3) is a covalent and irreversible TEAD inhibitor with IC50s of 385, 143, 558 and 173 nM for TEAD1, TEAD2, TEAD3 and TEAD4. MYF-03-69 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity (IC50 = 56 nM) and up-regulates apoptosis gene BMF. MYF-03-69 selectively inhibits mesothelioma cancer cells with defective Hippo signaling. MYF-03-69 can be used for the study of malignant pleural mesothelioma (MPM) .
    MYF-03-69
  • HY-15948
    Kif15-IN-1
    4 Publications Verification

    		 Kinesin Cardiovascular Disease Inflammation/Immunology Cancer
    Kif15-IN-1 is an inhibitor of the mitotic Kinesin family member 15 (Kif15), and is used for the research of cellular proliferative diseases.
    Kif15-IN-1
  • HY-175357
    YAP/TEAD-IN-2

    		YAP Cancer
    YAP/TEAD-IN-2 (Compound T-1) is a YAP/TEAD inhibitor. YAP/TEAD-IN-2 inhibits the luciferase activity driven by YAP/TEAD in 293T cells. YAP/TEAD-IN-2 exhibits strong anti-proliferative activity against human pleural mesothelioma NCI-H226 cells. YAP/TEAD-IN-2 can be used for the study of diseases associated with Hippo pathway dysregulation, particularly cancers .
    YAP/TEAD-IN-2
  • HY-B0988R
    Deferoxamine mesylate (Standard)

    Desferrioxamine B mesylate (Standard); DFOM (Standard)

    		 Reference Standards Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (mesylate) (Standard) is the analytical standard of Deferoxamine (mesylate). This product is intended for research and analytical applications. Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate (Standard)
  • HY-121538
    CUDA
    1 Publications Verification

    		 Epoxide Hydrolase PPAR Cardiovascular Disease
    CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .
    CUDA
  • HY-14614D
    S-Adenosyl-L-methionine iodide
    Maximum Cited Publications
    18 Publications Verification

    S-Adenosyl methionine iodide; Ademetionine iodide; AdoMet iodide

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) iodide is an orally active methyl group donor. S-Adenosyl-L-methionine iodide is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine iodide also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine iodide has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine iodide
  • HY-151289
    ALK5-IN-34

    		TGF-β Receptor TGF-beta/Smad Cancer
    ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC50 value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .
    ALK5-IN-34
  • HY-148215A
    Hsp90-IN-17 hydrochloride

    		HSP Neurological Disease Cancer
    Hsp90-IN-17 (Example 5) hydrochloride is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17 hydrochloride
  • HY-159647A
    (S,S)-PLX-4545

    		Molecular Glues IKZF Family Cancer
    (S,S)-PLX-4545 (Compound I) is an orally active and cereblon-based molecular glue degrader of IKZF2 (zinc finger transcription factor Helios). (S,S)-PLX-4545 can be used for the study of IKZF2-mediated diseases or disorders, such as proliferative diseases or disorders and/or cancer .
    (S,S)-PLX-4545
  • HY-P2758
    Diamine oxidase

    DAO

    		 Biochemical Assay Reagents Metabolic Disease Inflammation/Immunology Cancer
    Diamine oxidase (DAO) is an orally active enzyme. Diamine oxidase catalyzes oxidative deamination of various polyamines. Diamine oxidase degrades histamine and polyamines to maintain the metabolic balance of amines in the body. Diamine oxidase is a key regulatory enzyme in rapidly proliferating tissues such as bone marrow and intestinal mucosa. Diamine oxidase can be used in research related to intestinal diseases, small bowel transplant rejection, histamine intolerance, and other conditions .
    Diamine oxidase
  • HY-N12540
    Monogalactosyldiacylglycerol

    MGDG

    		 DNA/RNA Synthesis Apoptosis Others
    Monogalactosyldiacylglycerol (MGDG) is a galactolipid with anti-inflammatory and anticancer activities, which is found in photosynthetic organisms. Monogalactosyldiacylglycerol is a potent DNA polymerase inhibitor with pro-apoptotic activity. Monogalactosyldiacylglycerol inhibits the synthesis of LPS (HY-D1056)-induced inflammation-related proteins (Ex-FABP, Avidin, Serum Amyloid A). Monogalactosyldiacylglycerol exerts an anti-proliferative effect on chicken articular chondrocytes . Monogalactosyldiacylglycerol can be used in research related to osteoarthritis, cancer and inflammatory diseases .
    Monogalactosyldiacylglycerol
  • HY-B1153A
    Glafenine hydrochloride
    4 Publications Verification

    Glafenin hydrochloride

    		 COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Metabolic Disease Inflammation/Immunology
    Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine hydrochloride
  • HY-76711S
    Naltrexone-d4

    		Isotope-Labeled Compounds Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Naltrexone-d4 is deuterium labeled Naltrexone (HY-76711). Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone-d4
  • HY-119017
    SB-429201

    		HDAC Cancer
    SB-429201 is a potent and selective HDAC1 (IC50~1.5 μM). SB-429201 displays at least a 20-fold preference for HDAC1 inhibition over HDAC3 and HDAC8 .
    SB-429201
  • HY-118858
    UCPH-102

    		EAAT Neurological Disease Cancer
    UCPH-102 is a highly selective EAAT1 inhibitor with an IC50 of 0.43 µM. UCPH-102 exhibits a specific anti-proliferative effect on T-ALL cells. UCPH-102 also shows good blood-brain permeability, which can be used in studies of amyotrophic lateral sclerosis, Alzheimer’s disease, chronic pain and obsessive compulsive disorder .
    UCPH-102
  • HY-B0617AR
    S-Adenosyl-L-methionine tosylate (Standard)

    S-Adenosyl methionine tosylate (Standard); Ademetionine tosylate (Standard); AdoMet tosylate (Standard)

    		 Reference Standards Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine tosylate (Standard) (S-Adenosyl methionine tosylate (Standard)) is the analytical standard of S-Adenosyl-L-methionine tosylate (HY-B0617A). This product is intended for research and analytical applications. S-Adenosyl-L-methionine (S-Adenosyl methionine) tosylate is an orally active methyl group donor. S-Adenosyl-L-methionine tosylate is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine tosylate also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine tosylate has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine tosylate (Standard)
  • HY-B1153R
    Glafenine (Standard)

    Glafenin (Standard)

    		 COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reference Standards Metabolic Disease Inflammation/Immunology
    Glafenine (Standard) is the analytical standard of Glafenine. This product is intended for research and analytical applications. Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
    Glafenine (Standard)
  • HY-12812
    Autotaxin modulator 1

    		Phosphodiesterase (PDE) Neurological Disease Cancer
    Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer .
    Autotaxin modulator 1
  • HY-151275
    ALK5-IN-28

    		TGF-β Receptor TGF-beta/Smad Cancer
    ALK5-IN-28 (Compound Ex-05) is a selective ALK-5 inhibitor (IC50 ≤ 10 nM) that inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit tumor growth in vivo. ALK5-IN-28 can be used in the research of proliferative diseases such as cancer .
    ALK5-IN-28
  • HY-B1625R
    Deferoxamine (Standard)
    3 Publications Verification

    Deferoxamine B (Standard); Deferriferrioxamine B (Standard); Deferrioxamine (Standard)

    		 Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Standard) is the analytical standard of Deferoxamine. This product is intended for research and analytical applications. Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine (Standard)
  • HY-76711R
    Naltrexone (Standard)

    		Reference Standards Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Naltrexone (Standard) is the analytical standard of Naltrexone (HY-76711). This product is intended for research and analytical applications. Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
    Naltrexone (Standard)
  • HY-144867
    CCT245232

    		HSP Cancer
    CCT245232 is a potent inhibitor of heat shock factor 1 (HSF1). HSF1 is the master regulator of the heat shock response, in which multiple genes are induced in response to temperature increase and other stresses. CCT245232 has the potential for the research of proliferative diseases, such as cancer (extracted from patent WO2015049535A1) .
    CCT245232
  • HY-145025
    ERK1/2 inhibitor 3

    		ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1) .
    ERK1/2 inhibitor 3
  • HY-117810
    JAK2-IN-1

    		JAK Inflammation/Immunology
    JAK2-IN-1 (eExample 2) is a JAK2 inhibitor, and can be used for research of proliferative disease, inflammatory disease, or renal disease .
    JAK2-IN-1
  • HY-111424A
    (R)-BDP9066

    		Cdc42-binding kinase Cancer
    (R)-BDP9066 is an isomer of BDP9066 and has lower activity compared to BDP9066. BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 is derived from patent WO2019034890A1 (E118) .
    (R)-BDP9066
  • HY-121538A
    CUDA disodium
    1 Publications Verification

    		 Epoxide Hydrolase PPAR Cardiovascular Disease
    CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease .
    CUDA disodium
  • HY-B0617B
    S-Adenosyl-L-methionine 1,4-butanedisulfonate

    S-Adenosyl methionine 1,4-butanedisulfonate; Ademetionine 1,4-butanedisulfonate; AdoMet 1,4-butanedisulfonate

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) 1,4-butanedisulfonate is an orally active methyl group donor. S-Adenosyl-L-methionine 1,4-butanedisulfonate is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine 1,4-butanedisulfonate also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine 1,4-butanedisulfonate has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine 1,4-butanedisulfonate
  • HY-P991543
    BTI-322

    		CD2 Inflammation/Immunology Cancer
    BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .
    BTI-322
  • HY-153011
    ROCK-IN-5

    		ROCK ERK GSK-3 Cardiovascular Disease Neurological Disease
    ROCK-IN-5 (compound I-B-37) is a potent inhibitor of ROCK, ERK, GSK, and AGC protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research .
    ROCK-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: